Oxford Asset Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Oxford Asset Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-9,443	Closed	-$215K	–	1395
2019 Q4	$215K	Sell	9,443 -43,048	-82%	-$614K	0.01%	1535
2019 Q3	$751K	Sell	52,491 -1,218	-2%	-$17.9K	0.02%	1085
2019 Q2	$715K	Buy	53,709 +1,069	+2%	+$16.1K	0.02%	1123
2019 Q1	$914K	Sell	52,640 -13,661	-21%	-$204K	0.02%	965
2018 Q4	$907K	Buy	66,301 +30,214	+84%	+$532K	0.02%	916
2018 Q3	$805K	Buy	36,087 +26,309	+269%	+$800K	0.02%	1107
2018 Q2	$422K	Buy	9,778 +7,145	+271%	+$327K	0.01%	1400
2018 Q1	$172K	Sell	2,633 -2,728	-51%	-$193K	﹤0.01%	1499
2017 Q4	$399K	Buy	+5,361	New	+$443K	0.01%	1254
2016 Q2	–	Sell	-16,356	Closed	-$2.68M	–	891
2016 Q1	$2.68M	Sell	16,356 -7,258	-31%	-$1.47M	0.08%	307
2015 Q4	$7.76M	Buy	23,614 +6,709	+40%	+$2.18M	0.18%	109
2015 Q3	$5.45M	Buy	16,905 +1,106	+7%	+$486K	0.17%	115
2015 Q2	$6.29M	Buy	+15,799	New	+$6.71M	0.17%	134

Other funds holding LUMO

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

IFG

Investors Financial Group Plymouth, Minnesota $215M AUM 19.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Oxford Asset Management's LUMO Position: Q1 2020 in Review

Oxford Asset Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2020, closing a stake of 9,443 shares — an estimated $215K sold.

Oxford Asset Management first reported a position in LUMO in Q2 2015 and held it in 13 quarters. The position peaked at $7.76M in Q4 2015. 46 funds tracked by Wall St. Rank hold LUMO as of Q1 2020.

Oxford Asset Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 9,443 Lumos Pharma, Inc. Common Stock shares in Q1 2020, an estimated $215K.
Oxford Asset Management first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2015 and held it in 13 quarters.
Oxford Asset Management's Lumos Pharma, Inc. Common Stock position peaked at $7.76M in Q4 2015.
46 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.